FDA expands meningitis vaccine age range

Oct 18, 2007

The U.S. Food and Drug Administration has expanded the approved age range for Menactra, a bacterial meningitis vaccine.

Originally approved by the FDA in 2005 for use by people ages 11 to 55 years, it is now approved to include children ages 2 to 10 years.

Meningitis is a serious inflammation of the lining that surrounds the spinal cord and brain and can result in death or permanent injury.

Before Menactra's approval, Menomune was the only meningococcal vaccine available in the United States for use in children, ages 2 years and older. Both products are manufactured by Sanofi Pasteur Inc. of Swiftwater, Pa., and both offer protection against four groups of Neisseria meningitidis, the bacterium that can cause meningitis.

The Centers for Disease Control and Prevention recommends meningococcal vaccination for children ages 2 to 10 years who are at increased risk of meningococcal disease, such as those whose spleen has been removed; those with a medical condition that makes it difficult to fight infection; and those who expect to travel to areas where the disease is common.

Vaccination also is used to control outbreaks of bacterial meningitis.

Copyright 2007 by United Press International

Explore further: Bangladesh jails three over drug scam that killed hundreds of children (Update)

add to favorites email to friend print save as pdf

Related Stories

North Atlantic right whale's prospects tied to climate

12 minutes ago

A pleasant scientific surprise: The North Atlantic right whale population – once projected for extinction – exhibited an unexpected increase in calf production and population size during the past decade.

Finding the 'heart' of an obstacle to superconductivity

22 minutes ago

A team at Cornell and Brookhaven National Laboratory has discovered that previously observed density waves that seem to suppress superconductivity are linked to an electronic "broken symmetry," offering an ...

Heat testing the miniature Aausat 4 satellite

22 minutes ago

The miniature Aausat satellite undergoes repeated temperature variations in a vacuum chamber, cooling the CubeSat to –10°C and heating it to +45°C for more than two weeks. This harsh baptism will make ...

Recommended for you

Journal raises concern about blood-thinning drug

6 hours ago

A medical journal raised concerns Wednesday about a blood-thinning drug widely used by people at risk of stroke, accusing its manufacturer of concealing safety data and regulators of laxness.

Supermaterial gives rejected drugs a new chance

Jul 22, 2014

More than 80 percent of all drug candidates in the pharma R&D suffer from poor solubility and are therefore rejected early in the drug discovery process. Now Uppsala University researchers show that the new ...

Risk of antibiotic overuse in aged care settings

Jul 21, 2014

Antibiotics are being overused in residential aged care facilities (RACFs), and more integrated efforts to improve antibiotic prescribing practices need to be introduced, researchers say. 

User comments : 0